Key result
Darapladib inhibits Lp-PLA2 activity up to ~66% vs placebo in stable CHD on atorvastatin.
Why the study?
Does darapladib reduce Lp-PLA2 activity and inflammatory biomarkers in patients with stable coronary heart disease or CHD-risk equivalent receiving atorvastatin?
RCT (n=959)
randomized
Does darapladib reduce Lp-PLA2 activity and inflammatory biomarkers in patients with stable coronary heart disease or CHD-risk equivalent receiving atorvastatin?
Answers are grounded in this paper and cite their sources.
In patients with stable CHD on intensive atorvastatin therapy, darapladib produced sustained, dose-dependent inhibition of Lp-PLA2 activity and reduced IL-6 levels.
OBJECTIVES: This study examined the effects of darapladib, a selective lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inhibitor, on biomarkers of cardiovascular (CV) risk. BACKGROUND: Elevated Lp-PLA(2) levels are associated with an increased risk of CV events. METHODS: Coronary heart disease (CHD) and CHD-risk equivalent patients (n = 959) receiving atorvastatin (20 or 80 mg) were randomized to oral darapladib 40 mg, 80 mg, 160 mg, or placebo once daily for 12 weeks. Blood samples were analyzed for Lp-PLA(2) activity and other biomarkers. RESULTS: Baseline low-density lipoprotein cholesterol (LDL-C) was 67 +/- 22 mg/dl. Plasma Lp-PLA(2) was higher in older patients (>or=75 years), in men, in those taking atorvastatin 20 mg, at LDL-C >or=70 mg/dl or high-density lipoprotein cholesterol (HDL-C) <40 mg/dl, or in those with documented vascular disease (multivariate regression; p < 0.01). Darapladib 40, 80, and 160 mg inhibited Lp-PLA(2) activity by approximately 43%, 55%, and 66% compared with placebo (p < 0.001 weeks 4 and 12). Sustained dose-dependent inhibition was noted overall in both atorvastatin groups and at different baseline LDL-C (>or=70 vs. <70 mg/dl) and HDL-C (<40 vs. >or=40 mg/dl). At 12 weeks, darapladib 160 mg decreased interleukin (IL)-6 by 12.3% (95% confidence interval [CI] -22% to -1%; p = 0.028) and high-sensitivity C-reactive protein (hs-CRP) by 13.0% (95% CI -28% to +5%; p = 0.15) compared with placebo. The Lp-PLA(2) inhibition produced no detrimental effects on platelet biomarkers (P-selectin, CD40 ligand, urinary 11-dehydrothromboxane B(2)). No major safety concerns were noted. CONCLUSIONS: Darapladib produced sustained inhibition of plasma Lp-PLA(2) activity in patients receiving intensive atorvastatin therapy. Changes in IL-6 and hs-CRP after 12 weeks of darapladib 160 mg suggest a possible reduction in inflammatory burden. Further studies will determine whether Lp-PLA(2) inhibition is associated with favorable effects on CV events.
No takes yet. Share an insight, caveat, or question.
Mohler et al. (2008) conducted an RCT in Coronary heart disease (CHD) and CHD-risk equivalent (n=959). Darapladib vs. Placebo was evaluated on Lp-PLA(2) activity (43% to 66% inhibition, p=<0.001). Darapladib 40 to daily inhibited Lp-PLA(2) activity by 43% to 66% compared with placebo in patients with stable CHD receiving atorvastatin.
Synapse has enriched 10 related papers. Consider them for comparative context: